keyword
MENU ▼
Read by QxMD icon Read
search

Adjuvant chemotherapy and breast cancer

keyword
https://www.readbyqxmd.com/read/27912846/new-insights-and-evolving-role-of-pegylated-liposomal-doxorubicin-in-cancer-therapy
#1
REVIEW
Alberto A Gabizon, Yogita Patil, Ninh M La-Beck
We herein review various pharmacological and clinical aspects of pegylated liposomal doxorubicin (PLD), the first nanomedicine to be approved for cancer therapy, and discuss the gap between its potent antitumor activity in preclinical studies and its comparatively modest achievements in clinical studies and limited use in clinical practice. PLD is a complex formulation of doxorubicin based on pharmaceutical nanotechnology with unique pharmacokinetic and pharmacodynamic properties. Its long circulation time with stable retention of the payload and its accumulation in tumors with high vascular permeability both result in important advantages over conventional chemotherapy...
November 2016: Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
https://www.readbyqxmd.com/read/27912781/an-immune-stratification-reveals-a-subset-of-pd-1-lag-3-double-positive-triple-negative-breast-cancers
#2
Giulia Bottai, Carlotta Raschioni, Agnese Losurdo, Luca Di Tommaso, Corrado Tinterri, Rosalba Torrisi, Jorge S Reis-Filho, Massimo Roncalli, Christos Sotiriou, Armando Santoro, Alberto Mantovani, Sherene Loi, Libero Santarpia
BACKGROUND: Stromal tumor-infiltrating lymphocytes (TILs) are a robust prognostic factor in triple-negative breast cancer (TNBC). However, the clinical significance of TILs may be influenced by the complex landscape of the tumor immune microenvironment. In this study, we aimed to evaluate the composition and the functionality of lymphocytic infiltration and checkpoint receptors in TNBC. METHODS: Formalin-fixed, paraffin-embedded tissues were retrospectively collected from a cohort of patients with early-stage TNBC treated with adjuvant anthracycline-based chemotherapy (n = 259)...
December 3, 2016: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/27911866/dna-methylation-signature-sam40-identifies-subgroups-of-the-luminal-a-breast-cancer-samples-with-distinct-survival
#3
Thomas Fleischer, Jovana Klajic, Miriam Ragle Aure, Riku Louhimo, Arne V Pladsen, Lars Ottestad, Nizar Touleimat, Marko Laakso, Ann Rita Halvorsen, Grethe I Grenaker Alnæs, Margit L H Riis, Åslaug Helland, Sampsa Hautaniemi, Per Eystein Lønning, Bjørn Naume, Anne-Lise Børresen-Dale, Jörg Tost, Vessela N Kristensen
Breast cancer patients with Luminal A disease generally have a good prognosis, but among this patient group are patients with good prognosis that are currently overtreated with adjuvant chemotherapy, and also patients that have a bad prognosis and should be given more aggressive treatment. There is no available method for subclassification of this patient group. Here we present a DNA methylation signature (SAM40) that segregates Luminal A patients based on prognosis, and identify one good prognosis group and one bad prognosis group...
November 30, 2016: Oncotarget
https://www.readbyqxmd.com/read/27908586/standard-wide-local-excision-or-bilateral-reduction-mammoplasty-in-large-breasted-women-with-small-tumours-surgical-and-patient-reported-outcomes
#4
R Di Micco, R L O'Connell, P A Barry, N Roche, F A MacNeill, J E Rusby
INTRODUCTION: Oncoplastic breast surgery is used to extend the role of breast-conserving surgery (BCS) to women with an unfavourable tumour to breast volume ratio. However, large-breasted women with a relatively small breast cancer may be offered bilateral reduction mammoplasty (BRM) despite being suitable for standard BCS as the more complex surgery may have advantages in terms of patient satisfaction and reduced adverse effects of radiotherapy. PATIENT AND METHODS: This retrospective study evaluated surgical and patient-reported outcome measures (PROMs) in large-breasted women with early (<3 cm) breast cancer, who have undergone unilateral standard BCS or BRM...
November 17, 2016: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27906432/analysis-of-radiotherapy-optimization-regimens-after-modified-radical-mastectomy
#5
X-B Zhao, G-S Ren
OBJECTIVE: Concomitant chemo-radiotherapy after modified radical mastectomy for breast cancer is an effective means of achieving high survival rates. In this study different radiotherapy optimization regimens are compared to assess their effectiveness and toxicity rates. PATIENTS AND METHODS: 112 patients with modified radical mastectomy participated, and were randomly assigned to one of three groups, all receiving adjuvant chemotherapy for 4-6 weeks prior to radiotherapy: group A received intensity modulated radiotherapy (radiation dose (DT) 50 Gy, 2...
November 2016: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/27906044/high-mammographic-breast-density-predicts-locoregional-recurrence-after-modified-radical-mastectomy-for-invasive-breast-cancer-a-case-control-study
#6
Yu-Sen Huang, Jenny Ling-Yu Chen, Chiun-Sheng Huang, Sung-Hsin Kuo, Fu-Shan Jaw, Yao-Hui Tseng, Wei-Chun Ko, Yeun-Chung Chang
BACKGROUND: We aimed to evaluate the influence of mammographic breast density at diagnosis on the risk of cancer recurrence and survival outcomes in patients with invasive breast cancer after modified radical mastectomy. METHODS: This case-control study included 121 case-control pairs of women diagnosed with invasive breast cancer between 2004 and 2009, and who had undergone modified radical mastectomy and had mammographic breast density measured before or at diagnosis...
December 1, 2016: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/27905893/computational-prediction-of-multidisciplinary-team-decision-making-for-adjuvant-breast-cancer-drug-therapies-a-machine-learning-approach
#7
Frank P Y Lin, Adrian Pokorny, Christina Teng, Rachel Dear, Richard J Epstein
BACKGROUND: Multidisciplinary team (MDT) meetings are used to optimise expert decision-making about treatment options, but such expertise is not digitally transferable between centres. To help standardise medical decision-making, we developed a machine learning model designed to predict MDT decisions about adjuvant breast cancer treatments. METHODS: We analysed MDT decisions regarding adjuvant systemic therapy for 1065 breast cancer cases over eight years. Machine learning classifiers with and without bootstrap aggregation were correlated with MDT decisions (recommended, not recommended, or discussable) regarding adjuvant cytotoxic, endocrine and biologic/targeted therapies, then tested for predictability using stratified ten-fold cross-validations...
December 1, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27905324/primary-neuroendocrine-carcinoma-of-the-breast-a-single-center-experience-and-review-of-the-literature
#8
Paolo Locurto, Angelo Danilo Antona, Antonietta Grillo, Antonio Ciulla, Stefania Martorana, Calogero Cipolla, Giuseppa Graceffa, Salvatore Vieni
: Neuroendocrine carcinoma of the breast is an extremely rare tumor. A standard treatment has yet to be established because only a few cases have been reported in literature. The authors report five cases observed from January 2007 to December 2014 and a review of literature. Four patients underwent quadrantectomy and in two cases axillary nodal dissection and only one to mastectomy with axillary nodal dissection. Tumor size was from T1 to T2 with N0 to N1, according TNM classification...
November 28, 2016: Annali Italiani di Chirurgia
https://www.readbyqxmd.com/read/27903675/a-pam50-based-chemo-endocrine-score-for-hormone-receptor-positive-breast-cancer-with-an-intermediate-risk-of-relapse
#9
Aleix Prat, Ana Lluch, Arran K Turnbull, Anita K Dunbier, Lourdes Calvo, Joan Albanell, Juan de la Haba-Rodríguez, Angels Arcusa, Ignacio Chacón, Pedro Sánchez-Rovira, Arrate Plazaola, Montse Muñoz, Laia Paré, Joel S Parker, Nuria Ribelles, Begona Jimenez, Abdul Aziz Bin Aiderus, Rosalía Caballero, Barbara Adamo, Mitch Dowsett, Eva M Carrasco, Miguel Martín, J Michael Dixon, Charles M Perou, Emilio Alba
PURPOSE: Hormone receptor-positive (HR+) breast cancer is clinically and biologically heterogeneous and subgroups with different prognostic and treatment sensitivities need to be identified. EXPERIMENTAL DESIGN: Research-based PAM50 subtyping and expression of additional genes was performed on 63 patients with HR+/HER2- disease randomized to neoadjuvant multi-agent chemotherapy versus endocrine therapy in a phase II trial. The biology associated with treatment response was used to derive a PAM50-based Chemo-Endocrine Score (CES)...
November 30, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27899774/-a-review-multigene-assays-for-clinical-utility-in-breast-cancer
#10
Kazuhiro Araki, Yoshinori Ito
Multigene assays that simultaneously measure the expression of various breast cancer genes have been developed to guide the use of adjuvant chemotherapy in early breast cancer. The efficacy of adjuvant therapies depends on the recurrence risk for an individual patient. As a result, accurate prediction of the recurrence risk is vital for precise adjuvant chemotherapy in individual breast cancer patients. The recurrence risk as typically assessed by conventional examination of histological data of immuno-histological biomarkers(ER, PR, HER2, and Ki-67)is not sufficient to select subsets of patients...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/27896952/muscle-strength-in-breast-cancer-patients-receiving-different-treatment-regimes
#11
Oliver Klassen, Martina E Schmidt, Cornelia M Ulrich, Andreas Schneeweiss, Karin Potthoff, Karen Steindorf, Joachim Wiskemann
BACKGROUND: Muscle dysfunction and sarcopenia have been associated with poor performance status, an increased mortality risk, and greater side effects in oncologic patients. However, little is known about how performance is affected by cancer therapy. We investigated muscle strength in breast cancer patients in different adjuvant treatment settings and also compared it with data from healthy individuals. METHODS: Breast cancer patients (N = 255) from two randomized controlled exercise trials, staged 0-III and aged 54...
November 28, 2016: Journal of Cachexia, Sarcopenia and Muscle
https://www.readbyqxmd.com/read/27894335/everolimus-and-exemestane-in-long-survival-hormone-receptor-positive-male-breast-cancer-case-report
#12
Z Ballatore, M Pistelli, N Battelli, A Pagliacci, M De Lisa, R Berardi, S Cascinu
BACKGROUND: Male breast cancer is a rare event, accounting for approximately 1% of all breast carcinomas. Although men with breast cancer had poorer survival when compared with women, data on prognosis principally derive from retrospective studies and from extrapolation of female breast cancer series. We reported the case of a very long survival patient. CASE PRESENTATION: A caucasian 42-year-old man underwent radical mastectomy with axillary dissection for breast cancer in 1993...
November 28, 2016: BMC Research Notes
https://www.readbyqxmd.com/read/27893470/the-association-between-out-of-pocket-costs-and-adherence-to-adjuvant-endocrine-therapy-among-newly-diagnosed-breast-cancer-patients
#13
Albert J Farias, Ryan N Hansen, Steven B Zeliadt, India J Ornelas, Christopher I Li, Beti Thompson
OBJECTIVE: To determine how out-of-pocket costs for adjuvant endocrine therapy (AET) medication affects adherence among newly diagnosed breast cancer survivors with private health insurance who initiate therapy. MATERIALS AND METHODS: We examined medical and pharmacy claims for the 1-year period after initiating AET using the Truven Health Analytics MarketScan database. Adherence was defined as ≥80% proportion of days covered. Mean out-of-pocket costs for AET fill were measured as the sum of copayments, coinsurance, and deductibles and adjusted to 30-day amounts...
November 23, 2016: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27892670/impact-of-adjuvant-chemotherapy-in-elderly-breast-patients-in-taiwan-a-hospital-based-study
#14
Hsiu-Chuan Lee, Wei-Yu Chen, Wen- Tsung Huang, Kuo- Chen Cheng, Yu-Feng Tian, Chung-Han Ho, Chao- Jung Tsao, Yin- Hsun Feng
Purpose: Decisions as to whether to provide adjuvant treatment in older breast cancer patients remains challenging. Side effects of chemotherapy have to be weighed against life expectancy, comorbidities, functional status, and frailty. To aid decision-making, we retrospectively analyzed 110 women with breast cancer treated with a curative intention from 2006 to 2012. Survival data with clinical and pathological parameters were evaluated to address the role of adjuvant chemotherapy in this study population. Method: A total of 110 elderly (>70 years) patients that received mastectomy at two hospitals in Taiwan were observed retrospectively for a medium of 51 months...
January 10, 2016: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/27892665/thyroid-function-after-postoperative-radiation-therapy-in-patients-with-breast-cancer
#15
Edyta Wolny-Rokicka, Andrzej Tukiendorf, Jerzy Wydmański, Danuta Roszkowska, Bogusław Staniul, Agnieszka Zembroń-Łacny
Objective: The aim of this study was to assess thyroid function in breast cancer patients exposed to therapeutic external beam radiation. The focus was on possible progressive changes and any relationships between the incidence of primary hypothyroidism, the time required to become hypothyroid, and factors such as chemotherapy, hormonotherapy and immunotherapy. Materials and Methods: Seventy females undergoing 3D conformal and IMRT radiation therapy for breast cancers were enrolled in a non-randomized prospective study...
January 10, 2016: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/27889595/is-there-a-role-for-salvage-radiotherapy-in-locally-advanced-breast-cancer-refractory-to-neoadjuvant-chemotherapy
#16
R C Coelho, F M L Da Silva, I M L Do Carmo, B V Bonaccorsi, S M Hahn, L D Faroni
INTRODUCTION: Locally advanced breast cancer (LABC) is a major problem, especially in developing countries. The standard treatment for LABC is neoadjuvant chemotherapy, with or without anti-Her2 therapy, followed by surgery, radiotherapy, and adjuvant systemic treatment if appropriate. However, there are few data in the literature addressing alternatives when neoadjuvant chemotherapy fails to reduce the tumour for surgery. MATERIALS AND METHODS: We conducted a retrospective study including all patients who had non-metastatic LABC treated with neoadjuvant chemotherapy and who were not eligible for surgical resection; these patients were submitted to salvage radiotherapy (RTX) between January 2000 and December 2012 at the Brazilian National Cancer Institute...
November 24, 2016: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/27886643/cardiac-safety-of-adjuvant-non-pegylated-liposomal-doxorubicin-combined-with-cyclophosphamide-and-followed-by-paclitaxel-in-older-breast-cancer-patients
#17
Luigi Coltelli, Andrea Fontana, Sara Lucchesi, Laura Ginocchi, Guido Bocci, Mario Filidei, Marco Scalese, Giada Arrighi, Chiara Finale, Lorenzo Marcucci, Orlando Goletti, Barbara Salvadori, Ilaria Ferrarini, Eleonora Bona, Alfredo Falcone, Giacomo Allegrini
PURPOSE: To investigate the cardiac safety of adjuvant Non-Pegylated Liposomal Doxorubicin (NPL-DOX) combined to Cyclophosphamide (CTX) and followed by weekly Paclitaxel, in older patients (≥65 years) with diagnosis of high risk breast cancer. The main end point of this prospective study was the detection of early episodes of symptomatic congestive heart failure (CHF). METHODS: The cardiac function was evaluated by left ventricular ejection fraction (LVEF) measurements with repeated echocardiograms, performed 2 weeks before the beginning of chemotherapy and every 6 months, until 30 months after the study entry; then yearly for at least 5 years...
November 22, 2016: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/27884722/the-impact-of-age-on-quality-of-life-in-breast-cancer-patients-receiving-adjuvant-chemotherapy-a-comparative-analysis-from-the-prospective-multicenter-randomized-adebar-trial
#18
Elena Leinert, Susanne Singer, Wolfgang Janni, Nadia Harbeck, Tobias Weissenbacher, Brigitte Rack, Doris Augustin, Arthur Wischnik, Marion Kiechle, Johannes Ettl, Visnja Fink, Lukas Schwentner, Martin Eichler
BACKGROUND: Elderly breast cancer patients are affected by poorer quality of life (QoL) compared to younger patients. Because QoL has a relevant impact on guideline-adherent treatment, elderly breast cancer patients are often undertreated, especially with regard to adjuvant chemotherapy, and overall survival is decreased. Thus, understanding the impact of chemotherapy on QoL in elderly patients is crucial. This study compared QoL in patients aged < 65 years and 65 to 70 years receiving adjuvant chemotherapy as a secondary outcome in the prospective randomized multicenter ADEBAR trial...
October 19, 2016: Clinical Breast Cancer
https://www.readbyqxmd.com/read/27883296/adjuvant-trastuzumab-a-10-year-overview-of-its-benefit
#19
Matteo Lambertini, Noam F Pondé, Cinzia Solinas, Evandro de Azambuja
Anti-HER2 targeted therapy is one of the key advances in the treatment of breast cancer that have occurred in the last 20 years. In the adjuvant setting, the use of trastuzumab has led to prolonged and sustained survival benefit with very little toxicity as also confirmed by the 10-year follow-up results from the pivotal trials. Despite the survival improvement, several key issues are not entirely resolved in this field. These issues have led to multiple research efforts in de-escalating or escalating the standard treatment with chemotherapy and 1 year of adjuvant trastuzumab...
November 24, 2016: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/27875517/adjuvant-chemotherapy-and-her-2-directed-therapy-for-early-stage-breast-cancer-in-the-elderly
#20
J Sun, S Chia
There is a lack of sufficient evidence-based data defining the optimal adjuvant systemic therapies in older women. Recommendations are mainly based on retrospective studies, subgroup analyses within larger randomised trials and expert opinion. Treatment decisions should consider the functional fitness of the patient, co-morbidities, in addition to chronological age with the aim to balance risks and potential benefits from treatment(s). In this review, we discuss assessment tools to aid clinicians to select elderly patients who are 'fit' for chemotherapy, and review the literature on the use of chemotherapy and of the anti-HER 2 antibody trastuzumab in this population...
November 22, 2016: British Journal of Cancer
keyword
keyword
31152
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"